<DOC>
	<DOCNO>NCT02437903</DOCNO>
	<brief_summary>This study determine efficacy safety JUVÉDERM VOLUMA™ XC use facial temporal region base change score investigator 's Temporal . This study open label , single center study .</brief_summary>
	<brief_title>Open Label Study Evaluating Efficacy Safety JUVÉDERM VOLUMA™ XC Facial Temporal Regions</brief_title>
	<detailed_description>Volume deficit temporal area ( side forehead ) face common sign age . JUVÉDERM VOLUMA™ XC dermal filler , FDA-approved October 2013 improvement correction age-related volume deficit mid-face area . JUVÉDERM VOLUMA™ XC gel implant compose 20 mg/mL hyaluronic acid ( HA ) formulation , produce Streptococcus equi bacteria , 0.3 w/w lidocaine . JUVÉDERM VOLUMA™ XC clear , sterile , biodegradable gel indicate subcutaneous and/or supraperiosteal injection . JUVÉDERM VOLUMA™ XCwill inject temple area subject follow 12 month .</detailed_description>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Willing able read sign inform consent study document . Treating investigator 's score 3 , 4 , 5 Temporal Fossa Rating Scale . Written inform consent obtain prior studyrelated procedure . Written Authorization Use Release Health Research Study Information sign . Ability follow study instruction complete study assessment tool include subject diary Female patient childbearing potential must negative urine pregnancy test result lactating . Likely complete require visit plan move Miami next 12 month Agree undergo treatment cosmetic procedure treatment area study facial laser treatment , botulinum toxin , hyaluronic acid injection , subcutaneous fat injection , permanent semipermanent facial filler . Any uncontrolled systemic disease History follow condition : vision loss correct lenses LASIX surgery ; glaucoma , retinal detachment , macular degeneration , history multiple sclerosis optic neuritis , uncontrolled eye disease . Have history severe allergic/anaphylactic reaction multiple allergy . Conditions within treatment area include acne , scar , acute lupus erythematosus , dermatitis , melasma . Females plan become pregnant , pregnant , breastfeed . History current evidence drug alcohol abuse within 12 month prior screen visit Have severe thin skin , treatment area determine PI . Have undergone temporary facial dermal filler injection hyaluronic acidbased filler within 12 month treatment area . Have neuromodulator injection , mesotherapy , resurface ( laser ablative nonablative procedure ) within 5 month prior entry study planning undergo procedure time study . Have undergone facial plastic surgery ( exception rhinoplasty brow lift ) , tissue grafting , tissue augmentation silicone , fat , permanent semipermanent dermal filler plan undergo procedure affect treatment area , time study . Unwilling undergo injection temple area . Have history migraine frequent headache , determine PI . Have blindness partial vision loss either eye . Have receive therapy , , opinion investigator , could interfere safety efficacy evaluation . Current enrollment investigational drug device study participation study within 30 day entry study . Patient condition situation , investigator 's opinion , may put patient significant risk , may significantly interfere patient 's participation study . Have receive anticoagulation , antiplatelet , thrombolytic medication ( e.g. , warfarin ) , antiinflammatory drug ( NSAIDs , e.g. , aspirin , ibuprofen ) , substance know increase coagulation time 10 day pre 3 day post injection . A wash period 10 day allow . Have undergone immunosuppressive therapy , chemotherapy , biologics systemic corticosteroid within 3 month prior study visit .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>voluma temporal , facial , volume loss</keyword>
</DOC>